Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
复制标题
DOI：
10.1182/blood.v98.8.2319
复制
发表时间：
2001-10-15
期刊：
影响因子：
20.3
通讯作者：
Chastang, C
中科院分区：
文献类型：
--
作者：
Leporrier, M;Chevret, S;Chastang, C
为比较氟达拉滨与CAP(环磷酰胺、多柔比星、强的松)和CHOP(环磷酰胺、长春新碱、强的松、阿霉素)方案对晚期慢性淋巴细胞白血病(CLL)的一线治疗效果，将初治的B、C期CLL患者随机分为CHOP、CAP或FAMP 3个月疗程，按Bnet分期分层。终点是总存活率、治疗反应和耐受性。从1990年6月1日到1998年4月15日，938名患者(651名B期和287名C期)在73个中心被随机分组。与CHOP和FAMP相比，CAP的总缓解率较低(58.2%；CHOP，71.5%；FAMP；71.1%；P
To comparatively assess first-line treatment with fludarabine and 2 anthracycline-containing regimens, namely CAP (cyclophosphamide, doxorubicin plus prednisone) and ChOP (cyclophosphamide, vincristine, prednisone plus doxorubicin), in advanced stages of chronic lymphocytic leukemia (CLL), previously untreated patients with stage B or C CLL were randomly allocated to receive 6 monthly courses of either ChOP, CAP, or fludarabine (FAMP), stratified based on the Binet stages. End points were overall survival, treatment response, and tolerance. From June 1, 1990 to April 15, 1998, 938 patients (651 stage B and 287 stage C) were randomized in 73 centers. Compared to ChOP and FAMP, CAP induced lower overall remission rates (58.2%; ChOP, 71.5%; FAMP; 71.1%; P